论文部分内容阅读
[目的]探讨改良型三联疗法(泮托拉唑、阿莫西林和甲硝唑维B6)治疗幽门螺杆菌(Hp)感染相关性消化性溃疡(PU)的临床疗效及安全性。[方法]156例Hp阳性PU患者,随机分为观察组80例和对照组76例,观察组予以泮托拉唑、阿莫西林和甲硝唑维B6,对照组予以奥美拉唑、阿莫西林和甲硝唑,均按药物推荐剂量使用,连续服用2周。观察2组临床总有效率、Hp根除率及不良反应。[结果]观察组与对照组临床总有效率分别为93.75%、82.89%,症状缓解率分别为93.75%、81.58%,溃疡愈合率分别为91.25%、80.26%,Hp根除率分别为95.00%、85.53%,不良反应发生率分别为3.75%、13.16%;2组各指标比较,差异均有统计学意义(均P<0.05)。[结论]以泮托拉唑、阿莫西林和甲硝唑维B6的改良型三联疗法抗Hp感染相关性PU,具有溃疡愈合迅速、Hp清除率和临床有效率高、不良反应轻微的特点,是一种较为理想的治疗方案,适合基层医院使用。
[Objective] To explore the clinical efficacy and safety of modified triple therapy (pantoprazole, amoxicillin and metronidazole B6) in the treatment of peptic ulcer associated with Helicobacter pylori (Hp) infection. [Methods] One hundred and fifty-six patients with Hp-positive PU were randomly divided into observation group (80 cases) and control group (76 cases). The observation group was treated with pantoprazole, amoxicillin and metronidazole. The control group was omeprazole Moxillin and metronidazole, according to the recommended dose of the drug used for two consecutive weeks. The total clinical effective rate, Hp eradication rate and adverse reactions in the two groups were observed. [Results] The total clinical effective rates in the observation group and the control group were 93.75% and 82.89%, respectively, and the rates of symptom remission were 93.75% and 81.58% respectively. The healing rates of ulcer were 91.25% and 80.26%, and the eradication rates of Hp were 95.00% The incidences of adverse reactions were 3.75% and 13.16% respectively. There were significant differences between the two groups (all P <0.05). [Conclusion] The modified triple therapy with pantoprazole, amoxicillin and metronidazole V6 has the characteristic of anti-Hp infection-related PU, which has the characteristics of rapid healing of ulcer, high Hp clearance and clinical efficiency, and mild adverse reactions. Is a more ideal treatment, suitable for primary hospital use.